Posted: November 03, 2004
UNTHSC TO HOST CONFERENCE ON FUTURE OF HORMONE REPLACEMENT THERAPY NOV. 5-7
The New York Academy of Science and the University of North Texas Health Science Center’s Office of Professional and Continuing Education will host a two-day conference on estrogen and hormone replacement therapy Nov. 5- 7 at the Renaissance Worthington Hotel in Fort Worth.
“Some of the best minds in the field of estrogen and hormone replacement therapy are all going to convene this weekend to determine what’s the appropriate population to study, how long after menopause to give hormone replacement therapy, what are the best hormones to use, and how do we best speed up clinical trials and keep them safe,” said James Simpkins, Ph.D., chairman of the Department of Pharmacology and Neuroscience at the UNT Health Science Center, who is a speaker at the conference.
Meharvan Singh, Ph.D., assistant professor of Pharmacology and Neuroscience at the UNT Health Science Center will also speak at the conference.
“At this program, we’re going to discuss if hormone replacement therapy is safe,” Dr. Simpkins said. “If so, when is it safe, what kind of treatment is safe and for how long is it safe.”
The conference, which is part of the Consortium for the Assessment of Research on Progestins and Estrogens is called “The Future of Estrogen and Hormone Replacement Therapy in Post Menopausal Women: What Basic Science and Clinical Studies Teach Us.”
Saturday’s sessions will include two hours of discussion, updating the participants on the status of clinical trials, followed by a discussion of the optimal time for undergoing hormone replacement therapy.
From the meetings on Saturday and Sunday, Dr. Simpkins said that the group hopes to produce a textbook through the New York Academy of Science.
“We want it to be a critical but fair assessment of clinical trials thus far,” Dr. Simpkins said, “and discuss where we need to go from here.”
According to research done by S. Mitchell Harman, M.D., Ph.D., with the Kronos Longevity Research Institute, who will also be at the conference, early hormone therapy is protective.
“That’s extremely important for women to know,” Dr. Simpkins said, “because early post menopausal hormone therapy is not only safe, it’s beneficial.”
The objectives of the conference are to identify current research on hormone replacement therapy, describe the potential for future therapies based on current research, and identify future areas of research-related hormone therapy to be conducted by basic scientists, epidemiologists and practicing clinicians.
Contact: Kay Colley at 817-735-2553, cell 817-980-5090, e-mail email@example.com.
If you are with the media and need additional information or would like to
arrange an interview, please contact the Office of Marketing and Communications at 817-735-2446.